Determinación de la actividad antiviral in vitro de derivados de miricetina de Marcetia taxifolia contra los virus del chikungunya, zika y dengue.
Share
Date
2022-11-18
Authors
Publisher
Universidad Antonio Nariño
Campus
Faculty
Program
Degree obtained
Document type
COAR type
http://purl.org/coar/resource_type/c_7a1f
Citation
Bibliographic Managers
Document Viewer
Select a file to preview:
item.page.resume
Abstract
Zika, dengue and chikungunya viruses are implicated in emerging and re-emerging epidemics in tropical
and subtropical countries such as Colombia, becoming a public health problem, with a negative impact
on the quality of life of the population due to the morbidity and mortality associated with their sequelae.
Today there is no specific antiviral treatment, only for dengue there is a vaccine whose efficacy is not
clear. This makes the development of therapeutic agents essential. Plants are a key point in the search
for new molecules with potential biological action since their compounds have medicinal properties.
Marcetia taxifolia is a shrub of the Melastomataceae family, for which secondary metabolites have been
described with in vitro antiviral activity against the human immunodeficiency virus type 1. Preclinical
evaluations of potential antivirals require reliable and reproducible methods. For this reason, an RTqPCR method was standardized for the detection and quantification of viral RNA from cell cultures,
with efficiencies of 100.6%, 99.63% and 100.8%, for chikungunya, zika and dengue-2, respectively.
BHK-21 was selected as the cell line that allows greater viral replication of clinical isolates compared
to Vero. Additionally, the antiviral activity of derivatives of the extract of Marcetia taxifolia myricetin3-rhamnoside and myricetin-3-(6-rhamnogalactoside) was evaluated in the developed in vitro model,
obtaining that the two compounds presented promising EC50 < 50µg/mL against the three viruses, on
the other hand the lower effectiveness of myricetin-3-(6-rhamnogalactoside) in the case of chikungunya
and zika. These data provide the first evidence for the in vitro anti-chikungunya, anti-Zika and antidengue-2 activity of myricetin-3-rhamnoside and myricetin-3-(6-rhamnogalactoside).